The proliferation of MC/9 cells treated with increasing concentrations of mIL-10 in the presence of 1 pg/ml mouse IL-4 (#5208) was assessed. After 72 hour treatment with mIL-10 cells, were incubated with a tetrazolium salt and the OD450-OD650 was determined.
The purity of recombinant mIL-10 was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant mIL-10 and staining overnight with Coomassie Blue.
Western blot analysis of extracts from MC/9 cells, untreated or treated with mIL-10 for 20 minutes, using Phospho-Stat3 (Tyr705) (D3A7) XP® Rabbit mAb #9145 (upper) or Stat3 Antibody #9132 (lower).
With carrier: A 0.22 μm filtered solution of 0.33 mg/ml mIL-10 in PBS, pH 7.2 containing 20 μg BSA per 1 μg mIL-10. Carrier free: A 0.22 μm filtered solution of 0.33 mg/ml mIL-10 in PBS, pH 7.2.
Stable at -20°C for 1 year after receipt. Maintain sterility. Do not store frozen.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant mIL-10. All lots are greater than 98% pure.
Recombinant mIL-10 does not have a Met on the amino terminus and has a calculated MW of 18,976. DTT-reduced and non-reduced protein migrate as 19 kDa polypeptides. The expected amino-terminal SRGQY of recombinant mIL-10 was verified by amino acid sequencing.
Recombinant mouse IL-10 (mIL-10) Ser19 - Ser178 (Accession # NP_034678) was produced in E. coli at Cell Signaling Technology.
IL-10 is an anti-inflammatory cytokine that is produced by T cells, NK cells, and macrophages (1,2). IL-10 initiates signal transduction by binding to a cell surface receptor complex consisting of IL-10 RI and IL-10 RII (1). Binding of IL-10 leads to the activation of Jak1 and Tyk2, which phosphorylates Stat3 (1,3). The anti-inflammatory activity of IL-10 is due to its ability to block signaling through other cytokine receptors, notably IFNγ receptor, by upregulating expression of SOCS1 (1,3). In addition, IL-10 promotes T cell tolerance by inhibiting tyrosine phosphorylation of CD28 (4,5). IL-10 is an important negative regulator of the immune response, which allows for maintenance of pregnancy (1). In contrast, increased IL-10 levels contribute to persistent Leishmania major infections (6).
Explore pathways + proteins related to this product.
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST's products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST's Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.